{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T22:47:54Z","timestamp":1762296474450},"reference-count":29,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":202,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[2001,6]]},"abstract":"<jats:p> <jats:bold>Objective:<\/jats:bold> To determine the prognosis in 86 new patients with social anxiety disorder.<\/jats:p><jats:p> <jats:bold>Method:<\/jats:bold> Untreated subjects with social anxiety were recruited by advertising in Stockholm, randomized to 3 months treatment with paroxetine or placebo, and then offered continued specialist care. Metabolizing capacity was determined by genotyping CYP2D6 in the subjects on paroxetine. After a mean 32 months all were contacted for a personal interview.<\/jats:p><jats:p> <jats:bold>Results:<\/jats:bold> Of the 92 evaluable subjects, 86 (93%) were interviewed. A favourable prognosis was seen in the subjects randomized to paroxetine who chose to continue with serotonergic medication. The least favourable prognosis was in those given placebo who chose not to be treated after the trial. Twenty\u2010four subjects were still symptomatic and dysfunctional and had not sought treatment. Drug\u2010induced adverse effects caused treatment termination in six subjects, one of whom had a poor metabolizing genotype.<\/jats:p><jats:p> <jats:bold>Conclusion:<\/jats:bold> Due to their condition, some subjects with social anxiety refrain from effective treatments. The efficacy of serotonergic medication was maintained and augmented after a mean period of 32 months.<\/jats:p>","DOI":"10.1034\/j.1600-0447.2001.00320.x","type":"journal-article","created":{"date-parts":[[2003,3,10]],"date-time":"2003-03-10T10:05:32Z","timestamp":1047290732000},"page":"447-452","source":"Crossref","is-referenced-by-count":15,"title":["A prospective study of 86 new patients with social anxiety disorder"],"prefix":"10.1111","volume":"103","author":[{"given":"Christer","family":"Allgulander","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291799008399"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-199612000-00003"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1781(94)90019-1"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199709000-00001"},{"key":"e_1_2_6_6_2","unstructured":"HairT KumarR RolfeTE.Maintained efficacy of parox\u2010etine in the treatment of social anxiety disorder. American Psychiatric Association Annual Meeting abstract no. NR656 Chicago2000."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-199405000-00008"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/0005-7967(91)90072-B"},{"key":"e_1_2_6_9_2","unstructured":"SteinDJ SteinMB LydiardRB PittsCD OakesR HunterB.Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of three placebo\u2010controlled paroxetine trials. Poster 152nd APA meeting Washington DC1999."},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0193-953X(18)30025-X"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.9.10.2215"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1999.tb10845.x"},{"key":"e_1_2_6_13_2","first-page":"22","article-title":"The Mini International Neuropsychiatric Interview (MINI): The development and validation of a structured diagnostic interview","volume":"59","author":"Sheehan DV","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(1997)6:2<47::AID-DA1>3.0.CO;2-2"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-199606003-00015"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.2190\/T8EM-C8YH-373N-1UWD"},{"key":"e_1_2_6_17_2","first-page":"12","article-title":"How is recovery from social anxiety disorder defined?","volume":"59","author":"Bobes J","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_18_2","first-page":"54","article-title":"Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety","volume":"59","author":"Ballenger JC","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199957040-00005"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(98)00126-7"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1992.2"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00316090"},{"key":"e_1_2_6_23_2","volume-title":"Inter\u2010national Agency for Research on Cancer Scientific Publica\u2010tion 32","author":"Breslow NE","year":"1980"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v61n0406"},{"key":"e_1_2_6_25_2","unstructured":"LicinioJ NegraoAB ProloP WongM\u2010L.Weight dys\u2010regulation: symptom and side effect. American Psychiatric Association 153rd Annual Meeting abstract no. 105C Chicago 2000."},{"key":"e_1_2_6_26_2","unstructured":"FurmarkT.Social phobia. From epidemiology to brain function. Uppsala University Sweden Doctoral Disser\u2010tation no. 97 Faculty of Social Sciences 2000."},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(00)00213-3"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199912020-00007"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200008002-00004"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(1999)10:3<89::AID-DA1>3.0.CO;2-5"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0447.2001.00320.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0447.2001.00320.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0447.2001.00320.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T18:30:44Z","timestamp":1697567444000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0447.2001.00320.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,6]]}},"alternative-id":["10.1034\/j.1600-0447.2001.00320.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0447.2001.00320.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,6]]}}}